Rucaparib was also demonstrated to show efficacy as maintenance therapy after first-line platinum-based chemotherapy in PC patients with germline or somatic BRCA1/2 or germline PALB2 mutations [159]. Here, BRCA1 is linked to pachyonychia congenita.